- Qiagen N.V. (NYSE:QGEN) clocked Q1 FY22 revenues of $628.4 million, +11% Y/Y, ahead of the outlook for at least 7% CER growth and well above the consensus of $517.8 million.
- At constant exchange rates (CER), Q1 revenues jumped 15% Y/Y.
- Sales were driven by 14% CER growth in the non-COVID-19 product portfolio and an 18% CER rise in sales of products used for COVID-19 testing and surveillance.
- COVID-19-related products, accounting for approximately 36% of total sales in Q1, increased 13% Y/Y to $229 million, while non-COVID products grew 10% to about $400 million.
- Adjusted EPS reached $0.80 ($0.83 CER), surpassing the consensus of $0.65 and prior company guidance of at least $0.72 CER.
- Guidance: Qiagen raised FY22 sales guidance to at least $2.12 billion CER (prior outlook for at least $2.07 billion), down from 2021 sales of $2.25 billion.
- The company forecasts adjusted EPS of at least $2.14 CER (prior outlook for at least $2.05).
- Price Action: QGEN shares are up 1.27% at $45.48 during the premarket session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks